CNS prophylaxis

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Diffuse Small Noncleaved-Cell/Burkitt Lymphoma / Treatment Options for Diffuse Small Noncleaved-Cell/Burkitt Lymphoma

Patients with diffuse small noncleaved-cell/Burkitt lymphoma have a 20% to 30% lifetime risk of CNS involvement. CNS prophylaxis with methotrexate is recommended for all patients and is usually given as four to six intrathecal injections.[10] For more information, see Acute Lymphoblastic Leukemia Treatment.

Source links and citations

Evidence (CNS prophylaxis):

In a series of 41 patients treated with systemic and intrathecal chemotherapy, 44% of those who presented with CNS disease and 13% of those who relapsed with CNS involvement became long-term disease-free survivors.[11] CNS relapse patterns were similar whether or not patients received radiation therapy, but increased neurological deficits were noted among those who received radiation therapy.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice